foretinib   

GtoPdb Ligand ID: 5679

Synonyms: EXEL-2880 | GSK 1363089G | GSK1363089 | XL 880
Compound class: Synthetic organic
Comment: Foretinib is a small molecule ATP-competitive inhibitor principally of the protein kinases c-Met (HGFR) and vascular endothelial growth factor receptor 2 (VEGFR2, aka KDR) [4].
2D Structure
Click here for structure editor
Physico-chemical Properties
Hydrogen bond acceptors 7
Hydrogen bond donors 2
Rotatable bonds 14
Topological polar surface area 111.25
Molecular weight 632.24
XLogP 4.55
No. Lipinski's rules broken 1
SMILES / InChI / InChIKey
Canonical SMILES COc1cc2c(ccnc2cc1OCCCN1CCOCC1)Oc1ccc(cc1F)NC(=O)C1(CC1)C(=O)Nc1ccc(cc1)F
Isomeric SMILES COc1cc2c(ccnc2cc1OCCCN1CCOCC1)Oc1ccc(cc1F)NC(=O)C1(CC1)C(=O)Nc1ccc(cc1)F
InChI InChI=1S/C34H34F2N4O6/c1-43-30-20-25-27(21-31(30)45-16-2-13-40-14-17-44-18-15-40)37-12-9-28(25)46-29-8-7-24(19-26(29)36)39-33(42)34(10-11-34)32(41)38-23-5-3-22(35)4-6-23/h3-9,12,19-21H,2,10-11,13-18H2,1H3,(H,38,41)(H,39,42)
InChI Key CXQHYVUVSFXTMY-UHFFFAOYSA-N
No information available.
Summary of Clinical Use
Foretinib was evaluated in several Phase 2 clinical trials as a treatment for many cancer types, including recurrent or metastatic squamous cell cancer of the head and neck, metastatic gastric cancer, renal cell carcinoma (RCC), metastatic breast cancer and advanced or metastatic non-small cell lung cancer (NSCLC). Development was terminated at Phase 2.
Mechanism Of Action and Pharmacodynamic Effects
Foretinib acts to reduce tumour growth through inhibition of proliferation of tumour cells and inhibition of invasion and angiogenesis [4].